导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.50% | 2552/4773 |
| 近一周 | -1.77% | 2783/5465 |
| 近一月 | -3.45% | 2516/5421 |
| 近一季 | -6.18% | 2317/5231 |
| 近半年 | -1.40% | 1772/4920 |
| 近一年 | 2.68% | 2226/4394 |
| 近两年 | 47.69% | 1578/2954 |
| 近三年 | 29.45% | 1106/2253 |
| 成立以来 | 46.35% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.63% 3318/4961 |
12.52% 2165/5312 |
- - |
- - |
| 2025 | 19.94% 2163/4813 |
-1.00% 2520/3635 |
2.10% 1868/4076 |
17.86% 2417/4524 |
0.67% 1854/4813 |
| 2024 | 16.75% 769/3463 |
2.86% 683/2808 |
-1.26% 1010/3014 |
16.47% 1446/3129 |
-1.30% 1650/3463 |
| 2023 | -9.20% 1129/2656 |
4.21% 1020/2280 |
-3.88% 942/2385 |
-2.91% 787/2515 |
-6.64% 1854/2655 |
| 2022 | -19.25% 823/2207 |
-13.80% 841/1919 |
6.56% 667/2016 |
-13.58% 925/2113 |
1.73% 1164/2208 |
| 2021 | -3.47% 906/1822 |
-3.07% 751/1255 |
4.02% 934/1330 |
-5.74% 852/1466 |
1.56% 875/1822 |
| 2020 | 26.89% 591/1250 |
-9.72% 713/1028 |
12.82% 666/1067 |
10.38% 560/1164 |
12.86% 421/1184 |
| 2019 | - - |
- - |
-0.53% 272/804 |
0.35% 525/850 |
6.68% 575/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 工银沪深300指数C VS. 长安沪深300非周期A(740101) |